Johnson & Johnson: Can the Pipeline Actually Replace What Stelara Was?

Johnson & Johnson reports second-quarter earnings before the bell on July 15, with Wall Street watching whether the healthcare giant can sustain its recent momentum amid a volatile geopolitical backdrop. The central question is whether JNJ can deliver on elevated expectations—consensus now calls for $2.85 per share, up from prior estimates—while navigating supply chain pressures and currency headwinds stemming from the escalating U.S.-Iran conflict and oil price volatility. With the stock trading near recent highs and analyst sentiment firmly bullish, any disappointment could trigger an outsized reaction.

Part 1: Earnings Preview

Johnson & Johnson is a diversified healthcare conglomerate operating across three main segments: pharmaceuticals, medical devices, and consumer health products. The company's broad portfolio—from blockbuster drugs to surgical equipment and over-the-counter brands—makes it a bellwether for the global healthcare sector and a defensive holding in uncertain markets.

JNJ reports second-quarter results before the market opens on July 15, 2026, with analysts expecting earnings of $2.85 per share. The company most recently reported $2.70 per share for the first quarter of 2026. Compared to the same quarter last year, when JNJ posted $2.77 per share, the current estimate implies +2.89% year-over-year growth—a modest but steady expansion that reflects the company's resilient business model.

Three key themes define this earnings story:

1. Pharmaceutical Pipeline Strength: Investors are focused on whether JNJ's oncology and immunology franchises can offset patent expirations and generic competition. Recent analyst commentary highlights the importance of new drug launches and clinical trial updates, particularly in the high-margin pharmaceutical segment that drives the bulk of operating income.

2. Medical Device Recovery: The medical device segment has been recovering from pandemic-era procedure deferrals, and analysts are watching whether elective surgery volumes continue to normalize. Any signs of sustained growth in orthopedics and cardiovascular devices would support the bull case for accelerating earnings growth.

3. Geopolitical and Currency Headwinds: The escalating U.S.-Iran conflict and resulting oil price volatility—Brent crude recently hit a one-month high above $84—pose risks to input costs and foreign exchange rates. JNJ's global footprint means currency fluctuations and supply chain disruptions could weigh on margins, and management commentary on these factors will be closely scrutinized.

Leading analysts remain constructive heading into the print. The consensus has been revised upward—estimates rose from $2.77 to $2.85 over the past quarter—reflecting confidence in JNJ's ability to navigate a challenging macro environment. Analysts point to the company's diversified revenue base and pricing power as key advantages, though some caution that elevated expectations leave little room for error.

Part 2: Historical Earnings Performance

Johnson & Johnson has demonstrated a consistent pattern of exceeding analyst expectations, delivering positive earnings surprises in each of the past four quarters. The company beat estimates by +4.14% in June 2025, followed by more modest beats of +1.08%, +1.23%, and +1.12% in the subsequent three quarters. While the magnitude of the beats has narrowed—from over 4% a year ago to around 1% in recent quarters—the streak itself underscores JNJ's operational discipline and management's ability to guide conservatively.

The trend suggests a company that reliably meets or slightly exceeds expectations rather than delivering dramatic upside surprises. This consistency is typical of large-cap healthcare names with predictable cash flows, and it has likely contributed to the upward revision in consensus estimates heading into this quarter. However, the tightening beat margins also indicate that analysts have become more accurate in their forecasting, leaving less cushion for error. Any miss—or even an in-line result paired with cautious guidance—could disappoint investors who have grown accustomed to JNJ's steady outperformance.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Johnson & Johnson typically reports earnings before the market opens, meaning Day 0 captures the first full trading session of reaction, while Day +1 reflects follow-through momentum.

Historically, JNJ has exhibited moderate volatility around earnings, with an average absolute Day 0 move of 1.86% and an average intraday range of 3.73%. The stock tends to see most of its price action on the day of the report, with Day +1 moves averaging just 0.51% and a tighter range of 1.80%—suggesting that the market digests the results quickly and follow-through is limited.

The most recent earnings cycle in April 2026 saw a modest 0.90% gain on Day 0, well below the historical average, indicating a muted reaction to what was likely an in-line or slightly positive result. In contrast, the July 2025 report triggered a sharp 6.19% rally—an outlier that likely reflected a significant positive surprise or bullish guidance. For the upcoming release, investors should expect a move in the 2% to 3% range based on historical patterns, though the elevated geopolitical uncertainty and recent oil price volatility could amplify reactions if results or guidance deviate meaningfully from expectations.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 2.90% by the July 17 expiration, slightly above the stock's average historical Day 0 move of 1.86% but well within the typical intraday range of 3.73%. This suggests options traders are anticipating a moderately elevated reaction—likely reflecting the combination of heightened macro uncertainty and the stock's recent run-up—but not an outsized swing relative to JNJ's historical earnings behavior.

Part 3: What Analysts Are Saying

Analysts remain firmly bullish on Johnson & Johnson, with the stock carrying an average recommendation of 4.16 out of 5.00—solidly in "Buy" territory. The consensus is supported by 13 Strong Buy ratings and 3 Moderate Buy ratings, while 9 analysts rate the stock a Hold. Notably, there are zero Sell or Strong Sell ratings, underscoring broad confidence in JNJ's defensive qualities and growth prospects.

Sentiment has been unchanged over the past month, with the rating distribution holding steady at the same levels. This stability suggests analysts are comfortable with their current views and see no immediate catalysts to shift their stance ahead of the earnings release. The lack of downgrades is particularly notable given the recent geopolitical volatility, indicating that analysts view JNJ's diversified business model and strong balance sheet as insulating factors.

The consensus price target sits at $262.56, implying roughly 3.4% upside from the current price of $253.85. The range of targets is wide, spanning from a low of $210.00 to a high of $298.00, reflecting differing views on the pace of pharmaceutical pipeline growth and the impact of currency headwinds. Still, the mean target suggests analysts see limited near-term upside, with most of the bullish case likely contingent on sustained earnings growth and successful new product launches over the next 12 to 18 months.

Part 4: Technical Picture

Johnson & Johnson enters earnings with a strong technical setup, supported by a Barchart Technical Opinion of 88% Buy—unchanged from last week but up sharply from 56% Buy a month ago. This improvement reflects the stock's recent rally and positive momentum heading into the release.

Timeframe Analysis:

• Short-term (100% Buy): A perfect buy signal indicates near-term momentum is decisively positive, with the stock in a clear uptrend over the past few weeks.
• Medium-term (50% Buy): A moderate buy signal suggests some consolidation or choppiness in the intermediate timeframe, though the overall bias remains constructive.
• Long-term (100% Buy): A perfect buy signal reflects strong underlying strength in the longer-term trend, consistent with JNJ's steady climb over the past several months.

Trend Characteristics: The combination of Good strength and Average direction suggests the stock is in a healthy uptrend with solid momentum, though not yet in an overheated or parabolic phase—a supportive backdrop for earnings.

The stock is currently trading at $253.85, above its 20-day ($249.58), 50-day ($237.20), 100-day ($238.05), and 200-day ($221.87) moving averages, confirming the bullish trend across multiple timeframes. However, the stock has pulled back slightly from its 5-day ($258.22) and 10-day ($258.87) moving averages, suggesting some near-term profit-taking or consolidation ahead of the report.

Key resistance now sits near the recent highs around $258 to $260, while support is well-established at the 20-day moving average near $250. The overall technical setup is supportive heading into earnings, with the stock in a confirmed uptrend and holding above all major moving averages. However, the recent pullback from short-term highs suggests some caution among traders, and a disappointing result could see the stock test the 20-day moving average. Conversely, a strong beat and upbeat guidance could propel JNJ toward the high end of the analyst price target range near $298.